Please ensure Javascript is enabled for purposes of website accessibility

GlaxoSmithKline, Pfizer, and Shionogi's HIV Prevention Candidate Outperforms Gilead's Truvada

By Brian Orelli, PhD - May 19, 2020 at 2:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A study showed that cabotegravir works better than the current pre-exposure prophylaxis treatment, but there may be issues with getting it approved.

ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK -0.64%), Pfizer (PFE 0.61%), and Osaka-based Shionogi, has shown that an injection of cabotegravir every two months is more effective at preventing HIV than Gilead Sciences' (GILD 0.83%) Truvada, a once-daily pill which is already approved for use as a pre-exposure prophylaxis (PrEP).

People who took cabotegravir had an HIV incidence rate of 0.38%, compared to a 1.21% rate for the group that took Gilead's Truvada. Put another way, cabotegravir was 69% more effective at preventing the disease than Truvada.

One of the downsides of a medication that comes in the form of a once-daily pill is that people need to remember to take it daily or it becomes substantially less effective. A random blood sampling of people taking Truvada detected one of the components of Truvada at a substantial level in 87% of the samples.

Gloved hands giving an injection in a shoulder

Image source: Getty Images.

On the safety side, 80% of patients reported an injection site reaction with cabotegravir, but only 2% found the issue bad enough that it led them to drop out of the clinical trial.

ViiV plans to use the data to submit cabotegravir for FDA approval as a PrEP treatment, although the company didn't indicate the timing for the submission.

The lack of certainty as regards the timing of the marketing application is likely linked to a December complete response letter -- the Food and Drug Administration's euphemism for a rejection -- for cabotegravir in combination rilpivirine as a treatment for patients infected with HIV. The issue had to do with the chemistry manufacturing and controls section of the marketing application, but ViiV didn't go into detail about the exact issue nor did it speculate about how quickly it might be fixed.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.57 (0.61%) $0.30
GSK Stock Quote
GSK
GSK
$40.31 (-0.64%) $0.26
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$61.60 (0.83%) $0.51

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.